Financial Data and Key Metrics Changes - In Q4 2025, the company achieved record net sales of $118 million, representing a year-over-year growth of 27% [6][22] - The adjusted EBITDA for Q4 was $29 million, or 25% of net sales, compared to $20 million, or 21% of net sales in the prior year [26] - The net cash balance at year-end reached nearly $150 million, an increase of $63 million from the start of 2025 [4][29] Business Line Data and Key Metrics Changes - Wound care sales in Q4 were $79 million, up 28% year-over-year, while surgical sales were $39 million, reflecting a 25% increase [22] - The surgical business grew by 20% for the full year 2025, benefiting from investments made in the segment [5][12] Market Data and Key Metrics Changes - The wound care market is undergoing disruption due to changes in Medicare reimbursement rates, which went into effect on January 1st [4][10] - Claims processing has slowed in states under the WISeR model, affecting market dynamics and provider operations [9][10] Company Strategy and Development Direction - The company aims to innovate and diversify its product portfolio in both wound care and surgical segments, with a focus on achieving a balanced business mix [8][30] - A share repurchase program has been authorized, allowing the company to buy back up to $100 million in stock over the next two years [8][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the wound care market despite current disruptions, citing the company's competitive position to thrive post-reimbursement changes [10][12] - The guidance for full-year 2026 revenue is projected to be between $340 million and $360 million, with expectations for sequential growth throughout the year [19][56] Other Important Information - The company is nearing full enrollment for its EPIEFFECT randomized control trial, with results expected soon [7][11] - The company has launched new products, including AMNIOFIX Thyroid Shield, aimed at enhancing surgical outcomes [14][16] Q&A Session Summary Question: Guidance in a tough environment and market adjustments - Management anticipated market disruptions and noted ongoing adjustments in response to new reimbursement rules [34][35] Question: Sales force turnover and market outlook - Management is monitoring sales force dynamics and is flexible in adjusting resources based on market conditions [38] Question: Volume perspective in Q1 and market stabilization - A significant drop-off in volume was observed from Q4 to Q1, with expectations for recovery as the year progresses [43][48] Question: Revenue composition between wound and surgical - The revenue split is expected to be approximately 50/50 between surgical and wound care, with surgical growth anticipated to accelerate [54][56] Question: Commercial investments in surgical - The company has increased dedicated sales resources in the surgical business by about 50% over the past few years and plans to continue investing [59][60]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved record net sales of $118 million, representing a 27% year-over-year growth [6][22] - Adjusted EBITDA for the quarter was $29 million, or 25% of net sales, compared to $20 million, or 21% of net sales in the prior year [27] - The company ended the year with a net cash balance of $148 million, an increase of $24 million in the quarter and $63 million higher than the start of 2025 [5][28] Business Line Data and Key Metrics Changes - Wound care sales in Q4 2025 were $79 million, up 28% year-over-year, while surgical sales were $39 million, reflecting a 25% increase [22] - The surgical business grew 20% for the full year 2025, benefiting from investments made in the segment [6][12] Market Data and Key Metrics Changes - The wound care market is undergoing disruption due to changes in Medicare reimbursement rates, which went into effect on January 1st [5][10] - Claims processing has slowed in states under the WISeR model, affecting the overall market dynamics [9] Company Strategy and Development Direction - The company aims to innovate and diversify its product portfolio in both wound care and surgical businesses, with a focus on achieving higher growth in surgical products [8][12] - A share repurchase program has been authorized, allowing the company to buy back up to $100 million in stock over the next two years [8][20] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the wound care market despite near-term disruptions, citing the company's competitive position to thrive post-reimbursement changes [10][12] - Guidance for full-year 2026 revenue is projected to be between $340 million and $360 million, with expectations for sequential growth throughout the year [19][56] Other Important Information - The company is nearing full enrollment for its EPIEFFECT randomized control trial, with results expected soon [7][11] - The company has launched new products, including AMNIOFIX Thyroid Shield, aimed at enhancing surgical outcomes [12][16] Q&A Session Summary Question: Market adjustments and guidance - Management anticipated market disruptions due to new reimbursement rules and noted ongoing price adjustments and product dumping [34][36] Question: Volume perspective in Q1 - A significant drop-off in volume was observed from Q4 to Q1, with expectations for recovery as the year progresses [43][44] Question: Revenue composition for 2026 - The revenue split between surgical and wound care is expected to be approximately 50/50, with surgical growth anticipated to accelerate in the second half of the year [53][56]

Core Insights - MiMedx Group, Inc. celebrates the 15th anniversary of its flagship products, EPIFIX and AMNIOFIX, which are placental allografts used in wound care and surgical recovery settings [1][2] Company Overview - MiMedx is recognized as a pioneer and leader in providing healing solutions, focusing on chronic and hard-to-heal wounds with a diverse product portfolio for wound care, burn, and surgical applications [3] - The company's vision is to become the leading global provider of healing solutions through continuous innovation aimed at restoring quality of life [3] Product Impact - EPIFIX and AMNIOFIX have been instrumental in changing the paradigm of wound care treatment and surgical recovery, becoming the preferred choice across various surgical specialties due to their utility and handling characteristics [2] - The products have been extensively studied, appearing in nearly 100 clinical and scientific publications, including seven randomized controlled trials, making them the most studied placental allografts in the industry [2]

Financial Data and Key Metrics Changes - The company reported a record quarterly revenue of $114 million, representing a year-over-year growth of 35% [5][22] - Adjusted EBITDA for the quarter was $35 million, or 31% of net sales, compared to $18 million, or 22% of net sales in the prior year [27] - The adjusted gross profit margin was 88%, an increase of approximately 540 basis points compared to the same quarter last year [23] Business Line Data and Key Metrics Changes - Wound sales reached $77 million, reflecting a 40% increase year-over-year, while surgical sales were $37 million, up 26% [22] - The surgical business grew by 26% in Q3, driven by strong performance from AMNIOFIX and AMNIOEFFECT [22][23] Market Data and Key Metrics Changes - The company has over half of the target patients enrolled in the EPIEFFECT randomized controlled trial, with favorable interim analysis results [6][8] - The company expects to end the year with a net cash balance of more than $150 million, having ended Q3 with $124 million in net cash [6][27] Company Strategy and Development Direction - The top strategic priority is to innovate and diversify the product portfolio, with recent launches including EPIEFFECT, HELIOGEN, CELERA, and EMERGE [8][9] - The company is focused on enhancing customer intimacy through improved interactions and the MiMedx Connect portal, which saw nearly 60% sequential sales growth for orders managed within it [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position post-Medicare reimbursement reform, anticipating that product performance will drive selection rather than profit potential [16][19] - The company raised its full-year 2025 revenue growth guidance from low teens to mid to high teens, expecting adjusted EBITDA margin to be at least in the mid-20% range [18][19] Other Important Information - The company generated $29 million in free cash flow during the quarter, a record for the company [27] - Management highlighted the importance of upcoming Medicare reimbursement reforms and expressed optimism about the potential for market share growth as competitors may exit the market [16][19] Q&A Session Summary Question: Guidance for the rest of the year regarding contributions from wound versus surgical - Management expects strong uptake in the surgical suite and continued healthy growth in the wound business, although Q4 comparisons may be tougher due to prior sales turnover [31][32] Question: Preparations for post-January 1 reforms - Management is advocating for a level playing field and believes that the proposed reforms will benefit the company, allowing it to outperform the market [35][36] Question: Cash generation and expectations for year-end cash balance - The company clarified that the $150 million guidance refers to net cash, with gross cash expected to be in the high $160 million range [37] Question: Volume growth in the wound business - Management refrained from providing specific volume growth figures, citing various factors affecting volume per square centimeter [40][41] Question: Feedback on suggestions made to CMS - Management indicated that they have not received public feedback on their suggestions but are working through third-party advisors to communicate with CMS [42][43] Question: Local Coverage Determinations and clinical data submission - Management expressed confidence in the strength of the evidence for EPIEFFECT and stated that all necessary steps for reimbursement submission have been completed [45][46]

Investor Presentation January 2025 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding: Additional forward-looking statements may be identified by words such as "belie ...